Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: burmester m. J Cancer Res Clin Oncol. 2021 Jan;147(1):243-244. doi: 10.1007/s00432-020-03497-z. J Cancer Res Clin Oncol. 2021. PMID: 33346877 Free PMC article. No abstract available.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: burmester m. J Cancer Res Clin Oncol. 2021 Jan;147(1):235-242. doi: 10.1007/s00432-020-03327-2. Epub 2020 Sep 4. J Cancer Res Clin Oncol. 2021. PMID: 32886212 Free PMC article. Clinical Trial.
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T, Albers P, Bartkowiak D, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Wellek S, Schmidberger H, Grozinger K, Renner P, Schneider F, Burmester M, Stöckle M. Wiegel T, et al. Among authors: burmester m. J Cancer Res Clin Oncol. 2021 Apr;147(4):1273-1274. doi: 10.1007/s00432-021-03549-y. J Cancer Res Clin Oncol. 2021. PMID: 33625578 Free PMC article. No abstract available.
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
Albers P, Wiegel T, Schmidberger H, Bussar-Maatz R, Härter M, Kristiansen G, Martus P, Meisner C, Wellek S, Grozinger K, Renner P, Burmester M, Schneider F, Stöckle M. Albers P, et al. Among authors: burmester m. World J Urol. 2021 Jan;39(1):65-72. doi: 10.1007/s00345-020-03154-7. Epub 2020 Mar 18. World J Urol. 2021. PMID: 32189088 Free PMC article. Clinical Trial.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C. Al-Batran SE, et al. Among authors: burmester m. Ann Oncol. 2015 Jun;26(6):1244-1248. doi: 10.1093/annonc/mdv129. Epub 2015 Mar 9. Ann Oncol. 2015. PMID: 25755108 Free article.
cAMP triggers Na+ absorption by distal airway surface epithelium in cystic fibrosis swine.
Luan X, Le Y, Jagadeeshan S, Murray B, Carmalt JL, Duke T, Beazley S, Fujiyama M, Swekla K, Gray B, Burmester M, Campanucci VA, Shipley A, Machen TE, Tam JS, Ianowski JP. Luan X, et al. Among authors: burmester m. Cell Rep. 2021 Oct 5;37(1):109795. doi: 10.1016/j.celrep.2021.109795. Cell Rep. 2021. PMID: 34610318 Free article.
54 results